| Name | Title | Contact Details |
|---|---|---|
Yong Yang |
Senior Director, Enterprise Architecture and Strategy | Profile |
Dave Yanus |
VP RPA / Technology Solutions | Profile |
Ryan Ward |
VP - Information Security (IAM, Architecture and Service Continuity) | Profile |
Ryan Ward |
VP, Information Security Risk | Profile |
Andrea Papadopoulos |
Director of Information Security Architecture | Profile |
Fort Hudson Nursing Home Inc is a Fort Edward, NY-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Satori Labs is a Scotts Valley, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
For more than 100 years we`ve been 100 percent dedicated to kids. Children’s Healthcare of Atlanta, a not-for-profit organization, is dedicated to making kids better today and healthier tomorrow. Our specialized care helps children get better faster and live healthier lives. Managing more than 850,000 patient visits annually at three hospitals and 27 neighborhood locations, Children’s is the largest healthcare provider for children in Georgia and one of the largest pediatric clinical care providers in the country. Children’s offers access to more than 60 pediatric specialties and programs and is ranked among the top children’s hospitals in the country by U.S.News & World Report. With generous philanthropic and volunteer support, Children’s has impacted the lives of children in Georgia, the United States and throughout the world.
National Healthcare Review is a Jacksonville, FL-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Sernova Corp. is a clinical-stage biotechnology company that is developing its Cell Pouch System, a novel implantable and scalable medical device with immune protected therapeutic cells, for the treatment of chronic diseases such as insulin-dependent diabetes, thyroid disease, and blood disorders that include hemophilia A. On implantation, the Cell Pouch forms a natural vascularized tissue environment in the body for the long-term survival and function of therapeutic cells that release essential factors absent or deficient in patients with certain chronic diseases. Sernova is also advancing a proprietary technology to shield therapeutic cells from immune system attacks with the goal to eliminate the need for chronic, systemic immunosuppression. In May 2022, the Company announced a global strategic partnership with Evotec, providing Sernova with a potentially unlimited supply of insulin-producing islet cells to treat patients with insulin-dependent diabetes (type 1 and type 2). Sernova continues to progress additional development programs utilizing its Cell Pouch System: a cell therapy for hypothyroid disease resulting from thyroid gland removal and an ex-vivo lentiviral Factor VIII gene therapy for hemophilia A.